The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who failed either abiraterone (Abi) or enzalutamide (Enza)

Journal article

Peer reviewed

N.J. Vogelzang, N. Gabrail, Z. Malik, F. Volterra, L.T. Nordquist, R. Levin, P. Zhang and K. Zhou

Annals of oncology, Vol.30, p.v355

10/2019

Files and links (1)

url

https://doi.org/10.1093/annonc/mdz248.055View

Published (Version of record) Open

1 Record Views

Title: The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who failed either abiraterone (Abi) or enzalutamide (Enza)
Creators: N.J. Vogelzang - Comprehensive Cancer Centers of Nevada
N. Gabrail - Gabrail Cancer Center
Z. Malik - New York Oncology Hematology
F. Volterra - New York Oncology Hematology
L.T. Nordquist - Urology Cancer Center and GU Research Network
R. Levin - Chesapeake Urology Associates
P. Zhang
K. Zhou
Publication Details: Annals of oncology, Vol.30, p.v355
Identifiers: 991006262530602656
Academic Unit: Radiology
Language: English
Resource Type: Journal article